Advances in the Treatment of Lung Cancer
David P. Carbone, MD, PhD, from the The Ohio State University Wexner Medical Center, discusses advances in the treatment of lung cancer.
David P. Carbone, MD, PhD, Professor, Division of Medical Oncology, Director, Thoracic Oncology Center, The James, The Ohio State University Wexner Medical Center, discusses advances in the treatment of lung cancer.
Recent advances in immunotherapy of lung cancer are probably the most exciting aspect of lung cancer therapy in the last few years, Carbone says. There is a large portion of patients who do not have immediately actionable lesions identified by current gene sequencing methods. Immunotherapy is potentially effective in these patients and could provide a way to improve outcome even in patients with EGFR and ALK mutations in combination with other treatments.
Clinical Pearls
- A large portion of the patient population does not have immediately actionable lesions identified by current gene sequencing methods
- Immunotherapy is potentially effective for this group of patients
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
